microcirculationРегионарное кровообращение и микроциркуляцияRegional blood circulation and microcirculation1682-66552712-9756Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1682-6655-2018-17-2-57-63microcirculation-167Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИ (КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ)ORIGINAL ARTICLES (CLINICAL INVESTIGATIONS)Агонист рецептора глюкагоноподобного пептида-1 уменьшает дисфункцию эндотелия у больных сахарным диабетом 2-го типаGlucagon-like peptide-1 receptor agonist diminishes endothelial dysfunction in type 2 diabetic patientsСиманенковаА. В.SimanenkovaA. V.annasimanenkova@mail.ruМакароваМ. Н.MakarovaM. N.marian.inspiration@gmail.comВасинаЛ. В.VasinaL. V.lubov.vasina@gmail.comБутомоМ. И.ButomoM. I.mbutomo@mail.ruДораС. В.DoraS. V.doras2001@mail.ruШляхтоЕ. В.ShlyakhtoE. V.eshlyakhto@spmu.rssi.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education «Pavlov First Saint Petersburg State Medical University»Russian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education «Pavlov First Saint Petersburg State Medical University»; Federal State Budgetary Institution «Almazov National Medical Research Centre» of the Ministry of Health of the Russian FederationRussian Federation2018300620181725763Copyright © Симаненкова А.В., Макарова М.Н., Васина Л.В., Бутомо М.И., Дора С.В., Шляхто Е.В., 20182018Симаненкова А.В., Макарова М.Н., Васина Л.В., Бутомо М.И., Дора С.В., Шляхто Е.В.Simanenkova A.V., Makarova M.N., Vasina L.V., Butomo M.I., Dora S.V., Shlyakhto E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.microcirc.ru/jour/article/view/167

Цель - оценить эндотелиопротективное действие лираглутида (ЛИР). Материал и методы. У пациентов с СД 2-го типа с HbA1C 7,5-9,0 % 3 месяца титровалась доза метформина (МЕТ). Пациенты с HbA1C до 7,5 % стали группой 1 (МЕТ), более 7,5 % - группой 2 (МЕТ+ЛИР). Исходно, через 3, 6 и 9 месяцев определялся тканевой активатор плазминогена (t-PA), ингибитор активатора плазминогена-1 (PAI-1), эндотелин-1 (Э) крови. Результаты. PAI-1 был повышен в обеих группах и снижался. t-PA был в норме. Э был повышен исходно только в группе 2. Э в группе 1 в целом был в норме, но повышался при нарастании гликемии. В группе 2 Э снижался при нарастании и снижении гликемии. Выводы. Улучшение контроля гликемии уменьшает дисфункцию эндотелия. ЛИР улучшает вазомоторную функцию эндотелия, независимо от влияния на гликемию.

Objective. To evaluate liraglutide (LIR) endothelial protective action. Material and methods. Type 2 diabetic patients with HbA1C 7.5-9.0 % had metformin (MET) dose titrated for 3 months. Patients with HbA1C less than 7.5 % comprised group 1 (MET), more than 7.5 % - group 2 (MET+LIR). Blood concentrations of tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), endothelin-1 (E) were evaluated at baseline, in 3, 6 and 9 months. Results. PAI-1 was increased in both groups and gradually decreased. T-PA was normal. E was primarily increased only in group 2. E was normal in group 1 in general, but enlarged with glycaemia increase. E decreased in group 2 with glycaemia improvement and worsening. Conclusions. Glycaemia control improvement decreases endothelial dysfunction. LIR improves vasomotor endothelial function, independently on its influence on glycaemia.

сахарный диабет 2-го типаэндотелиальная дисфункцияагонист рецептора глюкагоноподобного пептида-1лираглутидtype 2 diabetes mellitusendothelial dysfunctionglucagon-like peptide-1 receptor agonistliraglutideReferencesAdly AAM, Elbarbary NS, Ismail EAR et al. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic microvascular complications and carotid intima media thickness. J Diabetes Complications. 2014;28(3):340-347. doi: 10.1016/j.jdiacomp.2014.01.011.Adly AAM, Elbarbary NS, Ismail EAR et al. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic microvascular complications and carotid intima media thickness. J Diabetes Complications. 2014;28(3):340-347. doi: 10.1016/j.jdiacomp.2014.01.011.Al-Hamodi Z, Ismail IS, Saif-Ali R et al. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol. 2011;18;10:23. doi: 10.1186/1475-2840-10-23.Al-Hamodi Z, Ismail IS, Saif-Ali R et al. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol. 2011;18;10:23. doi: 10.1186/1475-2840-10-23.Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One. 2011;6(8):e23570. doi: 10.1371/journal.pone.0023570.Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One. 2011;6(8):e23570. doi: 10.1371/journal.pone.0023570.Briyal S, Gulati A. Effect of liraglutide on oxidative stress and apoptosis in rats following focal cerebral ischemia. Critical Care Medicine. 2012;40(12):1-328. doi: 10.1097/01.ccm.0000424416.67430.bc.Briyal S, Gulati A. Effect of liraglutide on oxidative stress and apoptosis in rats following focal cerebral ischemia. Critical Care Medicine. 2012;40(12):1-328. doi: 10.1097/01.ccm.0000424416.67430.bc.Dokken BB, La Bonte LR, Davis-Gorman G, et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 2011;43(5):300-3005. doi: 10.1055/s-0031-1271777.Dokken BB, La Bonte LR, Davis-Gorman G, et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 2011;43(5):300-3005. doi: 10.1055/s-0031-1271777.Gaspari T, Welungoda I, Widdop RE et al. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model. Diab Vasc Dis Res. 2013;10(4):353-60. doi: 10.1177/1479164113481817.Gaspari T, Welungoda I, Widdop RE et al. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model. Diab Vasc Dis Res. 2013;10(4):353-60. doi: 10.1177/1479164113481817.IDF Diabetes Atlas. 8-th edition. 2017. Available at: http://www.diabetesatlas.org/across-the-globe.html (accessed 15.03.2018).IDF Diabetes Atlas. 8-th edition. 2017. Available at: http://www.diabetesatlas.org/across-the-globe.html (accessed 15.03.2018).Koska J. Incretins and preservation of endothelialfunction. Cardiovasc Hematol Agents Med Chem. 2012;10:295-308. doi: 10.2174/187152512803530289.Koska J. Incretins and preservation of endothelialfunction. Cardiovasc Hematol Agents Med Chem. 2012;10:295-308. doi: 10.2174/187152512803530289.Li PC, Liu LF, Jou MJ et al. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016;17(1):37. doi:10.1186/s12868-016-0272-9.Li PC, Liu LF, Jou MJ et al. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016;17(1):37. doi:10.1186/s12868-016-0272-9.Lonborg JL, Vejlstrup N, Kelbak H et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491-9. doi: 10.1093/eurheartj/ehr309.Lonborg JL, Vejlstrup N, Kelbak H et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491-9. doi: 10.1093/eurheartj/ehr309.Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975-983. doi: 10.2337/db08-1193.Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975-983. doi: 10.2337/db08-1193.Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98(5):408-13. doi: 10.1136/hrt.2010.219345.Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98(5):408-13. doi: 10.1136/hrt.2010.219345.Sarman B, Toth M, Somogyi A. Role of endothelin-1 in diabetes mellitus. Diabetes/Metabolism Reviews. 1998;14:171-175. doi: 10.1002/(SICI)1099-0895(199806)14:2.Sarman B, Toth M, Somogyi A. Role of endothelin-1 in diabetes mellitus. Diabetes/Metabolism Reviews. 1998;14:171-175. doi: 10.1002/(SICI)1099-0895(199806)14:2.Sato K, Kameda M, Yasuhara T et al. Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci. 2013;14(11):21513-21524. doi: 10.3390/ijms141121513.Sato K, Kameda M, Yasuhara T et al. Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci. 2013;14(11):21513-21524. doi: 10.3390/ijms141121513.Schneider JG, Tilly N, Hierl T et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15(11):967-972. doi: 10.1016/S0895-7061(02)03060-1.Schneider JG, Tilly N, Hierl T et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15(11):967-972. doi: 10.1016/S0895-7061(02)03060-1.Shiraki A, Oyama J, Komoda H et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-a-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis. 2012;221(2):375-382. doi: 10.1016/j.atherosclerosis.2011.12.039.Shiraki A, Oyama J, Komoda H et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-a-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis. 2012;221(2):375-382. doi: 10.1016/j.atherosclerosis.2011.12.039.Vicente MRV, Alameda C, Becerra A et al. Relationship between endothelin-1 levels in diabetics with and without microangiopathy and control subjects. Endocrine Abstracts. 2013;32:431. doi: 10.1530/endoabs.32.P431.Vicente MRV, Alameda C, Becerra A et al. Relationship between endothelin-1 levels in diabetics with and without microangiopathy and control subjects. Endocrine Abstracts. 2013;32:431. doi: 10.1530/endoabs.32.P431.Zeravica R, Ilincic B, Cabarkapa V et al. Plasma endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80(2):299-304. doi: 10.1016/j.diabres.2007.12.024.Zeravica R, Ilincic B, Cabarkapa V et al. Plasma endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80(2):299-304. doi: 10.1016/j.diabres.2007.12.024.Zhong Z-L, Chen S. Plasma Plasminogen Activator Inhibitor-1 Is Associated with End-Stage Proliferative Diabetic Retinopathy in the Northern Chinese Han Population. Exp Diabetes Res. 2012;2012:350852. doi: 10.1155/2012/350852.Zhong Z-L, Chen S. Plasma Plasminogen Activator Inhibitor-1 Is Associated with End-Stage Proliferative Diabetic Retinopathy in the Northern Chinese Han Population. Exp Diabetes Res. 2012;2012:350852. doi: 10.1155/2012/350852.

The authors declare that there are no conflicts of interest present.